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Osteoporosis is a skeletal disorder characterized by low bone mineral density (BMD) and deterioration of 
the bone architecture which compromises bone strength, predisposing it to an increase in the risk of 
fractures. The occurrence of osteoporosis increases as the population age increases, and is especially 
common in post-menopausal women. There are approximately 200 million people around the world who 
suffer from osteoporosis. It is anticipated that one-third of women and one-fifth of men over 50-years of 
age will experience an osteoporotic fracture in their lifetime
1
.  
 
Bone remodeling is a lifelong process. Mature bone is removed by a process of bone resorption by 
osteoclasts and new bone is formed by osteoblasts. The bone remodeling cycle controls the replacement 
of bone following injury, including large bone fractures and smaller micro-fractures. The remodeling 
process is regulated by balancing the bone formation and bone resorption processes. When the balance 
between bone formation and bone resorption is disrupted, a decrease in bone mineral density leading to 
osteoporosis can ensue. Osteocytes are another important bone cell type. Osteocytes are fully 
differentiated osteoblasts embedded in mineralized bone lacuna. They play a vital role in cellular 
communication and regulate the functions of both osteoblasts and osteoclasts. They are in direct 
communication with each other and with the other bone cell types through cytoplasmic membrane 
extensions known as dendritic spines, which travel through canaliculi within the bone matrix.  
 
Kalirin is a novel guanine nucleotide exchange factor (GEF) originally identified in the brain.  Several 
studies have reported that Kalirin is involved in the formation of the dendritic spines of neurons and 
intercellular synapses.  Recent studies conducted in Dr. Bruzzaniti’s laboratory demonstrated that Kalirin 
is expressed in osteoblasts and osteoclasts.  Female Kalirin-knockout (Kal-KO) mice exhibited 45% 
lower bone volume compared with wild type (WT) mice at 14 weeks of age, while Kal-KO male mice 
exhibited 19% lower bone volume than control male mice. In addition, a reduction in cortical area was 
found in Kal-KO female mice. These studies revealed that female Kal-KO mice are osteoporotic.  
 
Based on several findings, it was hypothesized that Kalirin may regulate the morphology and function of 
osteocytes; i) Kalirin is expressed in osteoblasts and osteoclasts, ii) Kalirin plays a role in regulating bone 
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mass, and iii) Kalirin regulates the cytoskeleton of neuronal cells. In the current study, the expression of 
Kalirin isoforms was examined in primary osteocytes and in the osteocytic cell line, MLO-Y4. The 
morphology of primary osteocytes from WT and Kal-KO mice were compared by microscopy and the 
expression level of important signaling proteins in osteocytes were determined by quantitative real-time 
PCR (QPCR).  In addition, the effects of Kalirin expression on the formation of cytoplasmic processes in 
MLO-Y4 cells were examined. Findings from this study provide insights into the role of Kalirin in 
osteocytes and its mechanisms of action in the regulation of bone mass.  
 
OBJECTIVES 
1. To determine the role of Kalirin in the regulation of osteocyte morphology and functions.  
2. To determine the expression of Kalirin in primary osteocytes and MLO-Y4 osteocytic cells.  
 
HYPOTHESES 
1. Osteocytes derived from WT mice will exhibit longer cytoplasmic processes and will exhibit 
differences in cellular functions compared with osteocytes from Kal-KO mice. 
2.  Overexpression of Kalirin in MLO-Y4 cells will lead to elongation of cytoplasmic processes and 
affect osteocyte functions. 
 
 
 
 
 
 
 
 
 
 
 
4 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
REVIEW OF LITERATURE 
 
 
 
 
 
 
 
 
 
 
  
 
5 
 
Bone modeling occurs during skeletal growth to increase the size of bones and alter their shape. Bone 
modeling occurs on the periosteal surface without prior bone resorption
2
. The deposition of osseous tissue 
at the periosteal surface increases the stiffness of bone, resulting in rapid strengthening of the cylindrical-
shaped bone. There are two types of bone formation processes: endochondral ossification and 
intramembranous ossification. During endochondral ossification, the cartilage scaffold is replaced by 
bone whereas during intramembranous ossification, bone formation occurs without an intermediate 
cartilage step
3
. Unlike bone modeling, bone remodeling is a surface-dependent process that does not lead 
to alteration of the size and shape of bone. It occurs on endocortical, intracortical and trabecular regions 
of the bone. The bone remodeling process starts with bone resorption by osteoclasts and takes 2-3 weeks 
and is then followed by a period of bone formation by osteoblasts, which occurs over 2-3 months
4
.  
 
Bone remodeling is regulated by three bone cell types; osteoclasts, osteoblasts and osteocytes. An 
equilibrium between bone formation and bone resorption is regulated by the coordinated activities of 
osteoclasts, osteoblasts and osteocytes
5,6
. An imbalance between osteoclast and/or osteoblast functions 
can lead to bone loss and osteoporosis. Osteoporosis is a skeletal disorder characterized by porous, thin 
and weak bones that become fragile and break easily. It occurs especially in women following 
menopause.  Osteoporosis causes 8.9 million fractures annually worldwide, most commonly occurring in 
the wrist, hip, and vertebrae 
7
. Osteoporosis medicaments are classified into 2 groups: anti-resorptives and 
anabolic drugs. Bisphosphonates, calcitonin, estrogen, and selective estrogen receptor modulators 
(SERMs) and Denosumab, an antibody to receptor activator of the nuclear factor kappa-B ligand 
(RANKL), are examples of anti-resorptive or anti-catabolic drugs. Bisphosphonates and calcitonin 
directly impair or inhibit osteoclast functions and induce the apoptosis of osteoclasts
8
, while estrogen and 
SERMs have agonistic effects on intracellular estrogen receptors resulting in increasing estrogen activity 
and a decrease in osteoclast survival which increases bone mineral density (BMD)
9
. Denosumab is a 
monoclonal antibody against RANKL that prevents RANKL from interacting with the RANK receptor on 
osteoclast precursor cells, thereby inhibiting osteoclastogenesis
10
. Strontium ranelate has both anti-
catabolic and anabolic effects by interacting with the RANKL pathway
11
 and stimulating β-catenin in 
Wnt-signaling pathway which promotes osteoblast activity
12
, respectively. The anabolic drugs induce 
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bone formation by activating the proliferation and inhibiting the apoptosis of osteoblasts
13
. Teriparatide 
(recombinant parathyroid hormone) is currently the only FDA-approved anabolic agent
1
. An alternate 
anabolic therapy currently in development is an antibody to sclerostin, the product of the SOST gene, 
which is secreted by osteocytes and promotes bone formation by osteoblasts. In a clinical study, 
administration of the anti-sclerostin antibody with exercise was shown to increase bone mass in patients 
by attenuating the antagonistic activity of sclerostin on canonical Wnt signaling, resulting in increased 
bone formation markers and decreased bone resorption markers
14
.          
 
Osteoclast differentiation and bone resorption 
Osteoclasts are multinucleated cells derived from the hematopoietic stem cell lineage and function in 
bone degradation and resorption. The number and differentiation of osteoclasts is regulated by osteoblasts 
and osteocytes, which secrete macrophage colony-stimulating factor (M-CSF) and RANKL
15
. RANKL 
binds to RANK receptors on osteoclast precursors, and together with the action of M-CSF, stimulates 
osteoclast proliferation and differentiation and leads to an increase in osteoclast numbers
16
. In an in vitro 
study using the MLO-Y4 osteocytic cell line, M-CSF and RANKL expression were identified which were 
localized to the cell surface and to cytoplasmic processes
17
. Isolated osteocytes were also shown to 
express greater amounts of RANKL than osteoblasts and bone marrow stromal cells
15
. Osteoprotegerin 
(OPG) is also secreted from osteoblasts and osteocytes and acts as a decoy receptor for RANKL to inhibit 
osteoclastogenesis
17
.  
 
The differentiation of osteoblasts into osteocytes 
Osteoblasts differentiate from osteoprogenitor cells or pre-osteoblasts, which are derived from the 
mesenchymal stem cells. Osteoblasts function in protein matrix secretion for bone generation
18
. This 
process is regulated by growth factors, hormones, and transcription factors (as shown in Figure 1)
19
. After 
completion of proliferation and differentiation, some osteoblasts change to become quiescent bone-lining 
cells or apoptotic cells, or alternatively, become embedded in the bone matrix and differentiate further to 
become osteocytes
5,20
.  Several key proteins expressed in osteoblasts are shown in Table 1.  
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During osteocyte differentiation (osteocytogenesis), cell motility is arrested and the cells become 
embedded in the secreted bone matrix and undergo alteration in cell morphology 
21
. During the process of 
osteocyte differentiation, actin cytoskeletal rearrangement leads to changes in cell shape from round to 
stellate or dendritic
22,23
.  Concomitant with morphological changes, there is a significant decrease in the 
expression and secretion of several osteoblast-related proteins, including collagen type I, alkaline 
phosphatase, osteocalcin, and bone sialoprotein
24
. In addition, there is an increase in the expression of 
intracellular proteins that are unique to osteocytes, such as dentin matrix protein 1 (DMP1), matrix 
extracellular phosphoglycoprotein (MEPE) or sclerostin (SOST), as listed in Figure 2. The functions of 
these proteins are summarized in Table 2. 
 
The biology of osteocytes 
Osteocytes make up 90% of the total number of bone cells dispersed in the bone matrix. Unlike the 
morphology of osteoblasts, which are cuboidal in shape, mature osteocytes are stellate in shape and 
contain multiple cytoplasmic processes
23
. Osteocytes are deeply embedded in the bone matrix where they 
reside within nests called lacuna. Small channels known as canaliculi contain the osteocyte cytoplasmic 
processes. Both lacuna and canaliculi form the lacuna-canalicular system. Osteocytes maintain a distance 
of 50-80 nm from their cell bodies/cytoplasmic processes to the walls of their lacuna or canaliculi
25
. 
These spaces are filled with periosteocytic fluid, which is essential for metabolite transport for cell 
viability
26
 and fibers for bridging osteocytes processes to the canaliculi walls
25
. The osteocytes in lacuna 
are surrounded by collagen type I. The formation of cytoplasmic processes depends on the cleavage of 
surrounding collagen type I by membrane-type matrix metalloproteinase-1 (MT1-MMP; MMP-14)
27-29
. In 
support of this, osteocytes from MT1-MMP-deficient mice showed shorter and fewer numbers of cellular 
processes than WT mice due to inadequate cleavage of the surrounding collagen type I
29
.        
 
The communication among several cell types is called multicellular syncytium (Figure 3)
30
. The 
cytoplasmic processes of osteocytes can contact the bone marrow, where they stimulate osteoclast 
differentiation. The cytoplasmic processes can also extend to the bone surface where they directly contact 
osteoblasts to promote bone formation
31,32
. The osteocyte cell body is polarized and the surface facing the 
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calcified matrix has shorter and thicker cytoplasmic processes with fewer organelles. In contrast, the cell 
surface facing the vascular space contains longer and thinner processes which are enriched with 
microtubules and microfilaments. These cytoplasmic processes are important in cell-cell communication 
via gap junctions at the tips of cytoplasmic processes. Connexin 43 is a major protein expressed at gap 
junctions, which allows cell-cell signaling of molecules smaller than 1.2 kDa
23
.  
 
Osteocytes also play an important function in mechanical stress detection and biochemical stimuli 
response
33
. Mechanical loading affects osteocytes by altering fluid flow along the lacuna-canalicular 
system
34
. Alteration of the flow of interstitial fluid in canaliculi results in deformation of the osteocyte 
plasma membrane. As a result, several intracellular signaling pathways and signaling molecules are 
activated and secreted. If there is a deficiency in mechanical loading, such as in an astronaut exposed to 
weightlessness, the secretion of osteoclast-inhibitory signals is decreased and pro-osteoclastogenesis 
signals are increased leading to a higher number of osteoclasts. When osteocytes respond to mechanical 
forces, they release prostaglandin E2 (PGE2) which stimulates osteoblast recruitment from the bone 
marrow and activates the Wnt/β-catenin signaling pathway35. Osteocytes also respond to mechanical 
loading by secreting nitric oxide, a stimulator of bone formation
36,37
. Bone formation is the physiological 
response to mechanical stress, whereas bone resorption is the reaction to unloading or skeletal disuse
36
.  
 
Osteocytes are also indirectly involved in osteoclastogenesis by stimulating osteoblasts to secrete 
RANKL, M-CSF
38
 and osteoprotegerin (OPG)
39
. Osteocytes are also able to produce RANKL, M-CSF, 
and OPG, which can have a direct effect in regulating osteoclastogenesis
40
. Mechanical stimulation 
inhibits the apoptosis of osteocytes and increases osteocyte viability
41
. In addition, the apoptosis of 
osteocytes regulates osteoclast activity
42
. When micro-damage of bone occurs, osteocyte apoptotic bodies 
are able to activate osteoclastogenesis. This process is RANKL independent, but involves the tumor 
necrosis factor (TNF)-α43.  
 
When osteocytes are defective in function, sclerosteosis can occur. Sclerosteosis is a life-threatening 
pathology due to a mutation in the SOST gene, which encodes sclerostin in osteocytes. Sclerostin 
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produced by osteocytes counteracts Wnt signaling in osteoblasts by competitively binding to low-density 
lipoprotein receptor-related proteins (LRP) 5/6 and leading to the inhibition of osteoblastic-mediated bone 
formation. Therefore, a decrease in sclerostin production results in the exaggeration of osteoblastic bone 
formation. The common features in sclerosteosis patients are expansion of the jaw and facial bones and 
thickening and sclerosis of the skull. These pathological conditions result in the entrapment of cranial 
nerves and an increase in intracranial pressure, which can result in impaction of the brainstem and leads 
to death
44
. 
 
The arrangement of osteocyte cytoplasmic processes 
The cytoplasmic processes of osteocytes are important in intercellular communication between 
osteocytes, osteoclasts, osteoblasts, or lining cells on the surface of bone
45
. Osteocyte processes are 
formed by reorganization of actin cytoskeleton
23
. Several actin-bundling proteins, such as CapG, Capzb, 
destrin, E11/gp38, α-actinin and fimbrin were detected in osteocytes. E11/gp38 regulates the dynamics of 
actin filaments by effecting the formation of cytoplasmic processes
46
. E11/gp38 interacts with the ezrin-
radixin-moiesin (ERM) complex, which activates the downstream pathway of RhoA GTPase to regulate 
the dynamics of actin cytoskeleton
47
.  
 
Guanosine triphosphate (GTP)-binding proteins of the RhoGTPase family, such as Rho, Rac and Cdc42, 
play vital roles in many intracellular activities, including; cell migration, synaptic development, 
generation of dendritic spines, endocytosis, and the rearrangement of actin cytoskeleton
48-50
. These 
GTPases are inactive when bound to guanosine diphosphate (GDP).  Guanine nucleotide exchange factors 
(GEFs) promote the dissociation of GDP and the binding of GTP to GTPases. Subsequently, GTPases are 
activated when bound to GTP
51,52
. The activated RhoGTPases bind effector molecules which are specific 
to selective Rho family members
31,53
. Consequently, signal transduction occurs from extracellular stimuli 
to activate intracellular pathways
48,54
.   
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A novel GEF protein, Kalirin 
In mammalian cells, the GTP-exchange factor proteins (GEFs) proteins are subdivided into 3 classes; Dbl 
homology-pleckstrin homology (DH-PH) domain, CDM and Zizimin homology (CZH) proteins, and 
DOCK-180 related proteins
50
. Almost all GEFs contain pleckstrin-homology (PH) domains. The function 
of the GEF domain is to catalyze the exchange reaction of GDP to GTP
55
. Different GEFs can activate 
more than one GTPase, while others can activate the same GTPases
55,56
. 
 
Kalirin is a multi-domain GEF protein belonging to the family of Dbl homology-pleckstrin homology 
proteins and contains two DH-PH domains. It is encoded by the Kalrn gene which undergoes alternative 
mRNA splicing, resulting in multiple isoforms
57
, such as Kalirin-7, Kalirin-9, and Kalirin-12. Kalirin-9 
and Kalirin-12 are highly expressed in developmentally embryonic stages. Their expression substantially 
decreases in adults and is correlated with an increase in the expression of Kalirin-7
58
. Kalirin-7 is the 
predominant isoform found almost entirely in postsynaptic terminals in the central nervous system
58
. The 
expression of Kalirin-7 is positively correlated with the formation of neuronal dendritic spines
58,59
 and the 
density of glutamatergic synapses in hippocampal pyramidal neurons
58
. The expression of Kalirin-7 in 
Sprague–Dawley rats is extremely low during the first 7 days after birth and then increases significantly 
after 2 weeks of age
60,61
. 
 
Kalirin has several functional domains as shown in Figure 4
62
. The sec14 domain is involved in lipid 
interactions
62
; the spectrin-like repeat regions interact with several proteins, such as peptidylglycine α-
amidating monooxygenase
63
, inducible nitric oxide synthase
64
, and Huntingtin-associated protein 1
65
. The 
N-terminal GEF domain binds to Rac1
66,67
 and RhoA
68
. Kalirin-9 and Kalirin-12 isoforms are longer than 
Kalirin-7 and both contain a second C-terminal GEF-domain, which is active against RhoA
66,67
. RhoGEFs 
contain the Dbl-homology (DH) domain followed by a pleckstrin homology (PH) domain. The GEF 
binding site for GTPases is on the DH domain, while the PH domain constitutes the catalytic activity for 
the DH domain
69
. The PDZ domain targets Kalirin to specific locations in the cells and mediates 
assembly of the multi-protein complexes
68
. Kalirin-12 is the largest Kalirin isoform and also has a C-
terminal immunoglobulin-fibronectin III (Ig-FNIII) domain and a serine-threonine (Ser-Thr) kinase 
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domain
70-72
.  Although the functions of Kalirin are still largely unknown, Kalirin has been shown to be 
involved in the outgrowth of axons
67
 and the formation of lamellipodia
73
 and filopodial neurites
67
. Kalirin 
has been shown to be expressed in several tissues, such as neurons, liver, muscles, heart, and endocrine 
cells. In neurons, overexpression of Kalirin-7 resulted in an increase in the density, size of dendritic 
spines, and the number of synapses
74
, while Kalirin-9 in cortical neurons induced the lengthening of 
neurites and had an influence on the morphology of neurons
67
. In addition, Kalirin-12 has been shown to 
interact via its Ig-FnIII region with the dynamin GTPase and affect actin cytoskeleton reorganization and 
endocytic trafficking
70
. 
 
Until recently, the skeletal role of Kalirin was unknown. Recent studies from Dr. Bruzzaniti’s laboratory 
have shown that Kalirin is expressed in osteoclasts and osteoblasts. Importantly, female mice lacking the 
Kalrn gene (Kal-KO) have 45% less trabecular bone mass by 14 weeks of age
75
, whereas male Kal-KO 
mice exhibit 19% bone loss. These findings suggest that Kalirin plays a role in the regulation of bone 
mass. Furthermore, studies from Dr. Bruzzaniti’s laboratory suggest that the bone phenotype of Kal-KO 
mice is in part due to defects in the function of both osteoclasts and osteoblasts. However, the role of 
Kalirin in the function of osteocytes remains to be determined. Given that Kalirin can influence actin 
remodeling, dendritic spine formation and the synapses of neurons, it was hypothesized that Kalirin 
regulates the cytoplasmic processes of osteocytes, which may affect their ability to communicate with 
each other and to regulate the functions of osteoblasts and osteoclasts.    
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1. Generation of Kalirin Knockout Mice 
Kalirin global knockout (Kal-KO) mice were generated by removing exon13 of the Kalrn gene. Exon 13 
encodes the spectrin region, which is a common region of all Kalirin major isoforms
76
. LoxP was 
introduced into the mice genome and flanked by loxP upstream and downstream of exon13. LoxP is a 
specific 34 base pair sequence having an 8-bp core sequence and two 13-bp inverted repeats. Cre 
recombinase is an enzyme recombining two loxP sites. The Cre-loxP recombination is able to delete 
loxP-flanked sequences. The Cre gene and loxP site are not naturally present in the mammalian genome. 
They are separately developed and then crossed to generate Cre-lox stain. Consequently, breeding of mice 
containing the Cre gene under control of the housekeeping gene promoter, hypoxanthine 
phosphoribosyltransferase 1 (HPRT) with Kalrn loxP mice results in progeny that lack all the major 
Kalirin isoforms in all tissues in mice. For all experiments, WT littermate mice were used as controls 
62
. 
 
2. Isolation of primary osteocytes from mice 
For the isolation of osteocytes from WT and Kal-KO mice, long bones (femurs and tibias) from the 
posterior legs of mice were collected in sterilized phosphate buffer saline (PBS). Soft tissue and periosteal 
tissue were removed by scraping. Both ends of tibias and femurs, including the growth plates, were 
removed. The cortical bone was separated from bone marrow by flushing with sterilized PBS (HyClone 
Laboratories, Inc., South Logan, Utah, USA) (Figure 5), followed by cutting into small pieces. The 
remaining soft tissue and bone marrow was removed by incubating in 5 ml of 300 collagenase digestive 
units (CDUs)/ml collagenase from Clostridium histolyticum type IA (Sigma-Aldrich Co. LLC, St. Louis, 
Missouri, USA) in α-Minimum Essential Medium (MEM) for 30 minutes in each digestion at 37°C under 
shaking conditions (200 rpm). The procedure was repeated 3 times, while the first fraction was discarded. 
After each sequential digestion, suspended cells were separated from bone pieces and collected by 
centrifugation. The bone pieces were washed 3 times with PBS. Then, they were alternatively incubated 
in 5 ml of ethylenediaminetetraacetic acid (EDTA) solution (Fisher Scientific, Pennsylvania, USA) and 
collagenase type IA another 6 times for osteocyte isolation
77
. The digest solution was centrifuged at 2000 
rpm for 5 minutes. Cells from fractions 2-5 were plated in osteoblast-culturing medium that consists of α-
Minimum Essential Medium (α-MEM) (HyClone Laboratories, Inc., South Logan, Utah, USA) with L-
14 
 
glutamine supplemented with 10% (v/v) fetal bovine serum (FBS) (BioWest, Logan, Utah, USA) and 100 
U/ml penicillin/100 µg/ml streptomycin (Lonza Walkersville, Inc., Walkersville, Maryland, USA). The 
cells from fractions 7-9 were re-suspended in 10% serum-osteocyte culturing medium, which consists of 
α-MEM with L-glutamine supplemented with 5% (v/v) FBS, 5% (v/v) bovine calf serum (BCS) 
(HyClone Laboratories, Inc., South Logan, Utah, USA) and 100 U/ml penicillin/100 µg/ml streptomycin, 
and plated in petri dishes coated with 0.01% calf skin collagen type I and grown for 1 month. The length 
and number of cytoplasmic processes were then observed under the microscope (Leica DMI4000B, 
Wetzlar, Germany). Wilcoxon rank sum tests were performed to analyze the data between the WT and 
Kal-KO groups with a 5% significance level. The remaining cortical bones were washed in sterilized PBS 
and crushed after freezing in liquid nitrogen. The crushed bone was submerged in Trizol (Life 
Technologies Corporation, Carlsbad, California, USA) and kept in -80⁰C for RNA extraction.  
  
3. Scanning electron microscope analysis of osteocyte morphology  
Mice long bones were isolated. Bone samples embedded in methyl methacrylate (MMA) were polished 
and etched for 20 seconds by immersing each specimen in 9% phosphoric acid. Immediately following 
etching, each section was immersed in bleach for 5 minutes, followed by 1-2 seconds in dH2O. The 
sections were placed in a desiccator overnight and mounted on aluminum stubs using double-sided tape. 
The specimens were then sputter-coated with 3-5 nm of gold palladium at 2.5kV at 20mA for 105 
seconds with a Polaron E5000S and then viewed on the JSM JEOL-6390LV scanning electron 
microscope (JEOL USA Inc., Massachusetts, USA) operated at an accelerating voltage of 5kV.   
 
4. Osteocyte staining 
Long bones from 14 week-old mice were isolated, cleaned, and then submerged in 1% basic fuchsin and 
40% ethanol for 4 weeks. They were then immersed in copious amounts of tap water for 48 hours. The 
specimens were dehydrated, cut, and ground 50 µm thick and mounted on glass slides
78
. A number of 
osteocytes in the sections were observed under the microscope and counted from representative pictures 
that were taken from at least 5 different areas from one section. A total of 3 sections per bone specimen 
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were examined. The number of osteocytes in the WT and Kal-KO bone groups was statistically compared 
by Mixed-model ANOVA at a 5% significant level.     
 
5. Culturing of the osteocyte cell line (MLO-Y4)  
MLO-Y4 cells (murine long bone osteocyte Y4) were derived from the long bones of transgenic mice
79
. 
MLO-Y4 cells were grown in 5% serum-osteocyte culturing medium in an incubator at 37ºC with 5% 
CO2. When the cells were 80% confluent, they were washed twice with PBS and detached using a 0.05% 
trypsin/0.44 mM EDTA solution (Life Technologies Corporation, Carlsbad, California, USA) at 37ºC 
for 5 minutes. The action of trypsin/EDTA was neutralized by adding osteocyte-culturing medium, and 
the cell suspension was centrifuged at 2000 rpm for 5 minutes at 4°C. The cell pellet was re-suspended 
with fresh culturing medium and plated on 0.01% (w/v) collagen calfskin (Sigma-Aldrich Co. LLC, St. 
Louis, Missouri, USA) coated petri dishes.   
 
6. Plasmid purification 
Plasmid expression constructs for several of Kalirin’s functional domains were kindly provided by R.E. 
Mains, University of Connecticut Health Center, Connecticut, USA.  Schematic representation of their 
domain structure is shown in Figure 6A. The accession number for Kalirin is 032062.2. The 
pEGFP.HisMyc.Kal-kinase construct containing the EGFP domain (238 amino acids (aa)), a histidine tag 
(HHHHHH) followed by a myc tag (EQKLISEEDL), and the kinase domain of Kalirin-12 (aa 2632-
2959). A pCMS.HisMyc.Kal-kinase.EGFP construct contained the histidine and myc tags as well as the 
Kalirin-12 kinase domain but GFP was under the control of a separate promoter and was co-expressed 
with Kal-kinase in cells. The size of inserts is shown in Figure 6B.       
 
Five microlitres of each cDNA were added into one tube Oneshot Top10
®
 (Life Technologies 
Corporation, Carlsbad, California, USA). The Oneshot Top10 is commercial competent cells 
(Escherichia coli) with high efficiency cloning and plasmid propagation. The mixture was incubated on 
ice for 30 minutes, followed by heat shock in a water bath at 42⁰C for 30 seconds and then suddenly 
placed on ice for 2 minutes. Super Optimal broth with Catabolite repression (S.O.C) 250 μl was added 
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into the mixture and incubated at 37⁰C for 1 hour at 225 rpm in the shaker incubator. Then, 200 μl of 
cultured solution was spread on Luria-Bertani (LB) agar plates (DOT Scientific Inc., Burton, Michigan, 
USA) containing the 100 µg/ml ampicillin or 100 μg/ml kanamycin, depending on the types of cDNA and 
incubated overnight at 37⁰C. The single colony was picked and inoculated in 10 ml LB media with 
antibiotics and incubated at 37⁰C 200 rpm in the shaker incubator overnight. The culture was diluted in 
250 ml fresh LB broth and cultured under the same condition. Bacteria were then harvested by 
centrifugation at 6000 x g for 15 minutes at 4°C. Plasmids were purified by QIAGEN plasmid mini kit 
(QIAGEN, Hilden, Germany). The bacteria pellet was thoroughly re-suspended into 50 ml of re-
suspension buffer, and then mixed with 50 ml lysis buffer and incubated at room temperature. This 
solution was vigorously mixed with 50 ml chilled neutralization buffer to promote the precipitation of 
genomic DNA, proteins, and cell debris and incubated on ice for 30 minutes. Then the solution was 
centrifuged at 20000 x g for 30 minutes at 4°C. The columns were prepared by loading 10 ml 
equilibration buffer through the column due to gravity to reduce surface tension. The filter sheets were 
placed on top of the column. The supernatant containing plasmid DNA was loaded into the column and 
filtrated by gravity flow. All contaminants were washed out using 60 ml wash buffer. The DNA was 
eluted with 15 ml elution buffer. The DNA was precipitated by adding 10.5 ml room-temperature 
isopropanol into the eluted DNA, mixing vigorously, and centrifuging at 15000 x g for 30 minutes at 4°C. 
The DNA pellet was washed with 5 ml room-temperature 70% ethanol and centrifuged at 15000 x g for 
10 minutes. Finally, the pellet was eluted in Tris-EDTA (TE) buffer pH 8.0 at 4⁰C overnight and kept at -
20°C.   
 
7. Transient expression of Kalirin cDNA in MLO-Y4 cells    
Three million MLO-Y4 cells were cultured in collagen-coated petri dishes to obtain 80-90% confluence 
within 24 hours. They were trypsinized and washed with cold Ca
2+
/Mg
2+
-free PBS. The cell pellet was re-
suspended in 200 μl cold electroporation buffer (25 mM HEPES in PBS). The suspended cell solution 
(200 μl) was mixed with 100 μg DNA and incubated on ice for 15 minutes. The mixture was transferred 
into 2 mm plastic electroporation cuvettes. The cell-plasmid suspension was electroporated at 150 volts 
for 9 msec. The electroporated cells were left on ice for 5 minutes and then transferred into 10% serum-
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osteocyte culturing medium in a collagen-coated petri dish and on a cover-slip in 6-well plates. The 
expression of Kalirin in MLO-Y4 was detected by Western blot analysis, while the morphology of the 
Kalirin-expressing cells was determined by microscopic analysis after immunofluorescent staining of 
cells. 
 
8. Induction of cytoplasmic processes in MLO-Y4 cells 
MLO-Y4 cells (1x10
5
 cells) were cultured in the collagen-coated petri dishes and divided into 4 groups; 
one control group (cultured in osteocyte-culturing medium) and 4 treatment groups (cultured in osteocyte-
culturing medium with 0, 25, 50, and 75 ng/ml nerve growth factor (NGF)- or 50 mM potassium 
chloride (KCl) for 5 days. After treatment, the morphology of the cells was observed by microscopy.  
Alternatively, the cells were trypsinized, collected, and examined by Western blot analysis. 
 
9.  SDS-PAGE and Western blot analyses 
MLO-Y4 cells over-expressing the Kal-kinase domain or treated with NGF or KCl were lysed in SDS 
buffer (100 mM HCl, 500 mM Tris pH8.0, 10% SDS (wt/v) containing 10 µg/ml leupeptin hydrochloride, 
10 µg/ml aprotinin, and 10 µg/ml pepstatin), and sonicated for 2 minutes. The lysates were collected, 
centrifuged at 13,000 rpm for 5 minutes and the supernatant was collected. The amount of protein was 
estimated with the BCA protein analysis kit (Thermo Fisher Scientific Inc., Waltham, Massachusetts, 
USA) and 40 µg of protein was resolved by SDS-PAGE electrophoresis. Protein samples were mixed 
with loading buffer (62.5 mM Tris HCl pH 6.8, 2% w/v SDS, 10% glycerol, 50 mM DTT, and 0.01% 
bromophenol blue). All samples were boiled at 100°C for 5 minutes. The samples were loaded onto 4%-
12% NuPAGE Bis-Tris gels and subject to electrophoresis with NUPAGE MOPS (or MES) SDS 
Running Buffer (Life Technologies Corporation, Carlsbad, California, USA). Molecular weight protein 
markers were added and proteins were resolved at 120 volts, 3.0 amperes for approximately 2.5 hours. 
The proteins were transferred to nitrocellulose membrane in MOPS NuPAGE transfer buffer (Life 
Technologies Corporation, Carlsbad, California, USA) with 20% methanol at 100 volts for 1 hour at 
4°C. The membrane was washed with TBST solution (0.2 M Tris Base and 0.6 M NaCl at pH7.4 
containing 0.1% Tween-20) for 5 minutes at room temperature. Non-specific proteins were blocked with 
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5% skim milk in TBST solution for 1 hour, shaking. Primary antibodies (Table 3) were diluted (1:1000) 
in TBST buffer. The membrane was incubated with the primary antibody overnight at 4°C. The 
membrane was then washed 3 times for 15 minutes each with TBST buffer. An anti-mouse antibody 
conjugated with horseradish peroxidase (HRP) was diluted 1:20000, while anti-rabbit HRP was diluted 
1:10000 in the TBST buffer and incubated with the membrane for 1 hour at room temperature on the 
shaker. The membrane was washed 3 times for 15 minutes in TBST buffer and proteins were detected 
using the enhanced chemiluminescence (ECL) reagent (SuperSignal West Pico Chemiluminescent 
Substrate, Thermo Fisher Scientific Inc., Rockford, Illinois, USA) for 5 minutes according to the 
manufacturer’s instructions. Membranes were exposed to X-ray film (Thermo Fisher Scientific Inc., 
Waltham, Massachusetts, USA) and developed.      
 
10. Immunofluorescent staining 
Cells on glass cover slips were washed twice with PBS and fixed with 10% formaldehyde in PBS for 15 
minutes, followed by washing twice with PBS. The cells to be stained for actin filaments with rhodamine 
phalloidin were permeabilized by acetone treatment for 3 minutes, followed by washing twice with PBS. 
Non-specific proteins were blocked with blocking solution (0.1% bovine serum albumin (BSA), 0.05% 
saponin, and 5% goat serum) at room temperature for 30 minutes. The blocking solution was removed. 
Primary antibody, rabbit polyclonal anti-Kalirin antibody, was diluted 1:200 in the blocking solution. The 
cover slips were incubated for 2 hours at room temperature. They were washed 3 times with blocking 
solution. The fluorescent-conjugated secondary antibody was diluted 1:100 in the blocking solution. The 
cells were incubated for 1 hour at room temperature and protected from light. They were washed 3 times 
with PBS. Rhodamine phalloidin diluted in blocking solution (1:200) was added to cells on cover slips for 
1 hour. Nuclei were labeled with Dapi diluted (1:600) in PBS. The cover slips were mounted with 
FluorSave medium (Calbiochem, Massachusettes, USA)  
 
11. Isolation of RNA from bones and MLO-Y4 cells 
For cell lines, the plate/flask was grown until 80% confluent and then washed, trypsinized, and 
centrifuged to collect the cells (Section 5). For cortical bones, the crushed bones in Trizol solution 
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(Section 2) were sonicated. The sample was then incubated at room temperature for 5 minutes to permit 
the dissociation of nucleoprotein complexes and centrifuged at 13,000 rpm for 10 minutes at 4°C. The 
supernatant containing RNA was collected in new microcentrifuge tubes. A phase separation was 
performed by adding 200 µl of chloroform into the RNA solution and centrifuged at 13,000 rpm for 15 
minutes at 4°C. The top clear liquid with RNA was transferred into a new tube. To precipitate the RNA, 
500 µl of absolute isopropyl alcohol was added, incubated at room temperature for 10 minutes, and 
centrifuged at 13,0000 rpm for 10 minutes at 4°C. The supernatant was discarded. The RNA pellet was 
washed with 1 ml of cold 75% ethanol, vortexed, and centrifuged at 7,500 rpm for 5 minutes at 4°C. The 
RNA was then re-suspended in 100 µl of RNase-free water. The mRNA was purified using the RNeasy
®
 
Mini Kit (QIAGEN Sciences Inc., Germantown, Maryland, USA). Any remnant genomic DNA in the 
RNA samples was degraded by digestion with DNase I (Applied Biosystems, Warringtons, UK) by 
incubation at 37°C for 30 minutes. Then, 5 mM EDTA solution was added into the RNA-DNaseI solution 
and incubated at 75°C for 5 minutes to remove excess DNaseI. 
 
12. Generation of cDNA by reverse transcription reaction 
Complementary DNA (cDNA) was generated using the Transcriptor First Strand cDNA Synthesis Kit 
(Roche Applied Science, Mannheim, Germany), which used the reverse transcriptase (RT) and oligo 
(dT18) primers to convert mRNA to cDNA. For each reaction, 100 ng of mRNA was added. The solution 
was briefly centrifuged and then incubated on a thermal cycler (C1000, Bio-Rad Laboratories 
Headquarters, Hercules, California, USA) at 50°C for 60 minutes (for reverse transcriptase reaction with 
dNTPs) followed by heating at 85°C for 5 minutes (stop reaction) and at 4°C continually until the cDNA 
was stored at -20°C. 
 
13. Quantitative Real-time Polymerase Chain Reaction  
Quantitative polymerase chain reaction (QPCR) was used to quantify expression of mRNA from WT and 
Kal-KO osteocytes. Syber
®
 green Gene Expression Master Mix (Applied Biosystems, Warringtons, UK) 
was used. A list of the genes examined is shown in Table 4. All oligonucleotide primers were validated 
against their appropriate targets by sequence comparison and by reverse-transcription PCR and agarose 
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gel electrophoresis before being used for QPCR.   The 18S RNA housekeeping gene was used as an 
endogenous control. In each QPCR reaction, 100 ng of cDNA was added. All samples were centrifuged to 
collect reagents and then run in the QPCR machine (Applied Biosystems Prism 7000 using STEP1 
Software Solutions, Newbury Park, California, USA) in duplicate with the temperature profile: 50°C for 2 
minutes, 95°C for 10 minutes, and 50 repeating cycles of 95°C for 15 seconds and 56°C for 1 minute. In 
all experiments, the threshold cycle (Ct) for each test gene was normalized against its respective 
endogenous controls. Real-time PCR was analyzed in fold changes in expression relative to wild-type 
osteocytes with ΔCt values of the sample and reference gene using the formula 2-ΔΔCt.  
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1. Differential expression of Kalirin isoforms in primary osteocytes 
The role of Kalirin on osteocyte morphology and function was examined. First, the mRNA expression 
level for the Kalirin isoforms in cortical bone was examined. The isolated mRNA of osteocytes from 
cortical bone of mice tibias and femurs was reverse transcribed to cDNA (see section 11 and 12). The 
expression of Kalirin-7, Kalirin-9 and Kalirin-12 was examined by QPCR using isoform-specific 
oligonucleotide primers. In primary osteocytes, Kalirin-9 mRNA was found to be more abundant than 
Kalirin-12, followed by Kalirin-7 mRNA (Figure 7A).  
 
The mRNA expression level of the Kalirin isoforms was also examined in MLO-Y4 cells, an osteocytic 
cell line developed from murine long bones which was used for in vitro studies of Kalirin (see section 5). 
All 3 major isoforms of Kalirin were also detected in MLO-Y4 cells. Similar to primary osteocytes, 
Kalirin-9 mRNA was more abundant than Kalirin-12, while Kalirin-7 mRNA levels was found to be the 
least abundant of the Kalirin isoforms (data was not shown).  
 
Kalirin protein levels in MLO-Y4 cells was also examined by Western blotting using an antibody that 
detects all major Kalirin isoforms (anti-sec14 antibody) or using a Kalirin-12-specific antibody (Kal12) 
(provided by Drs. Main and Eipper, University of Connecticut Health Center, CT).  Western blot analysis 
revealed the expression of several Kalirin isoforms in MLO-Y4 cells (Figure 7B).  Based on the predicted 
molecular weight of the isoforms, these results indicated that Kalirin-7 protein levels were more abundant 
in MLO-Y4 cells than Kalirin-9. 
 
2. Kalirin is localized to the cytoplasmic extensions of osteocytes 
To further examine the expression of Kalirin in osteocytes, immunofluorescent staining of Kalirin in 
primary osteocytes and MLO-Y4 cells was performed. Primary calvarial osteoblasts were used as a 
positive control in these studies. Cells were plated on coverslips then fixed and labeled with an antibody 
to Kalirin (rabbit polyclonal anti-Kalirin antibody, Millipore Corporation, Billerica, MA, USA) (green).  
Cells were also co-stained for actin filaments using rhodamine phalloidin (red) or for nuclei using DAPI 
(blue) (Figure 8-10). In osteoblasts, Kalirin was found to be expressed at the perinuclear region and was 
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localized to actin-rich fibers/tubules that extended radially from the nucleus to the cell periphery.  
However, Kalirin was not detected in circular actin-rich fibers that surrounded the nucleus (Figure 8). In 
primary osteocytes, Kalirin was also expressed at the area close to the nucleus and was localized to actin-
rich cytoplasmic processes, often extending out to the tips of the processes in contact with an adjacent cell 
(Figure 9). Similar to osteoblasts, Kalirin was detected at the perinuclear area and along linear actin-rich 
fibers in MLO-Y4 cells (Figure 10). 
 
3. Osteocyte morphology is altered in the absence of Kalirin  
The role of Kalirin in regulating the morphology of the cytoplasmic processes in osteocytes was then 
examined in vivo and in vitro using WT and Kal-KO mice. Kal-KO mice were previously generated
80
 and 
lacked all three major Kalirin isoforms, as well as some minor isoforms
81
. First, the femurs of 14 week-
old mice Kal-KO and WT were isolated and the bones cleaned of tissue. The bones were stained with 
basic fuchsin, which stains the cell nucleus, and then sectioned and imaged (Figure 11A). The osteocyte 
cell bodies embedded in lacuna appeared dark red in color and multiple cytoplasmic processes were 
observed (Figure 11A). The number of osteocytes were counted and compared between WT and Kal-KO 
mice (n=3 in each group) from 5 random areas of bone sections. However, the number of osteocytes in 
WT (93.3±3.9) and Kal-KO (83.8±4) bones were not found to be significantly different (p>0.05) as 
determined by mixed-model ANOVA statistical analysis (Figure 11B). The number and morphology of 
osteocytes in cortical bone from Kal-KO and WT mice was also examined by acid-etching of plastic-
embedded bones specimens, followed by imaging using a scanning electron microscope (SEM). Although 
extensive cytoplasmic processes were observed in both WT and Kal-KO bones (Figure 12), no qualitative 
differences between Kal-KO and WT osteocytes were apparent, and further quantitative analyses were 
not possible with these specimens due to the large number of interconnected cytoplasmic extensions 
present.  
 
To better examine the effects of Kalirin deletion on osteocyte morphology, primary osteocytes from Kal-
KO and WT cortical and trabecular bones were used. Cells were isolated from the tibias and femurs of 
WT and Kal-KO mice by sequential collagenase digestion and then cultured in vitro for up to 1 month on 
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collagen-coated dishes. Osteocytes were then examined by microscopy for differences in length and 
number of cytoplasmic processes (Figure 13A). The average number of cytoplasmic processes detected in 
WT osteocytes (4.69±0.3) was significantly higher (p<0.05) than the average number of cytoplasmic 
processes found in Kal-KO osteocytes (3.32±0.21). In addition, the length of cytoplasmic processes of 
WT osteocytes (85.4±3.6 µm) was found to be significantly higher than the cytoplasmic processes of Kal-
KO osteocytes (79.5±4.6 µm) (Figure 13B).  These findings revealed that Kalirin played a crucial role in 
controlling the length and number of cytoplasmic processes of osteocytes. 
 
4.  Kalirin regulates mRNA levels of osteocyte genes 
Given that all 3 major Kalirin isoforms were detected in osteocytes and that osteocytes lacking Kalirin 
isoforms exhibited defects in the number and length of cytoplasmic processes, the role of Kalirin in 
regulating the function of osteocytes was examined. To this end, QPCR analysis of known osteocyte 
marker genes was performed. RNA was isolated from cortical bone of tibias and femurs of WT and Kal-
KO mice, reverse transcribed and subject to QPCR analysis using oligonucleotide primers to known 
osteocyte genes. The expression of 18S RNA was used as the endogenous control and results for Kal-KO 
osteocytes were normalized to WT levels (set as 1.0) (Figure 14). Statistical analysis of QPCR results 
from the WT and Kal-KO bone groups was performed by Wilcoxon rank sum tests (Figure 14).  
 
E11/gp38 is the earliest osteocyte-specific protein to be expressed in osteocytes as they become 
embedded in osteoid. MEPE and PHEX are also markers for osteocytes embedded in osteoid, and also 
function in regulating phosphate homeostasis
82
. QPCR analysis revealed that MEPE mRNA levels were 
significantly decreased (p<0.05) in Kal-KO bones compare to WT bones (Figure 14), whereas E11/gp38 
mRNA levels appeared normal. Dmp1 is also expressed in early mineralizing osteocytes and is a marker 
of osteoblasts transitioning into osteocytes. Similar to E11/gp38, the expression of Dmp1 mRNA was not 
found to be significantly different in Kal-KO osteocytes. Therefore, these findings suggest that in the 
absence of Kalirin, the differentiation of osteoblasts to early osteocytes appears normal, but osteoid 
formation and mineralization by osteocytes may be reduced.  
25 
 
IGF-1 is known to enhance the differentiation of late osteoblasts
83
 and to play a role in longitudinal bone 
growth
84
. The expression of IGF-1 was found to be significantly lower in Kal-KO bones than WT, which 
also implied the impairment of early osteocyte formation. FGF23 and SOST are both expressed in mature 
osteocytes. FGF23 plays a role in phosphate metabolism while the product of the SOST gene, sclerostin, 
is an inhibitor of Wnt signaling and inhibits the proliferation and differentiation of osteoblasts
85
. QPCR 
analysis revealed no change in FGF23 mRNA levels. However, SOST mRNA levels were significantly 
lower in Kal-KO than WT bones. ER-α and ER-β are known to be strongly expressed in cortical bone and 
cancellous bone, respectively
86
. The expression of ER-α mRNA in osteocytes was significantly decreased 
(p<0.05) in Kal-KO mice. On the contrary, the expression of ER- mRNA in Kal-KO bones was 
significantly increased (p<0.05) compared in WT bones. Finally, the ratio of RANKL and OPG is critical 
for the regulation of osteoclast differentiation. A significant decrease in OPG mRNA (p<0.05), but not 
RANKL mRNA (p>0.05) levels, was detected in Kal-KO bones compared to WT bones, suggesting a 
decrease in the RANKL/OPG ratio in Kal-KO mice, which would likely affect osteoclast number in these 
mice, consistent with unpublished studies from Dr. Bruzzaniti’s laboratory.   
 
5. Induction of cytoplasmic processes in MLO-Y4 cells regulates Kalirin, Rac1 and RhoA 
Examination of osteocyte morphology revealed Kal-KO osteocytes had shorter and fewer cytoplasmic 
processes than WT osteocytes, while immunofluorescent staining showed that Kalirin was expressed 
along the cytoplasmic processes of osteocytes. To begin to understand the intracellular signaling events 
leading to changes in cytoplasmic process formation, and to confirm Kalirin’s role in this process, two 
novel in vitro approaches to induce cytoplasmic process extension in ML0-Y4 cells were developed.  
Kalirin had previously been shown to play a role in neuronal dendrite formation downstream of nerve 
growth factor (NGF)-87. Furthermore, dendritic spine elongation in neurons was promoted using high 
extracellular levels of potassium chloride (KCl), which led to neuronal cell depolarization
88
. Therefore, 
cytoplasmic process elongation in MLO-Y4 cells was examined following treatment with NGF (0, 25, 50, 
75 ng/ml) or 50 mM KCl for 5-7 days. The NGF and KCl concentrations used and the time of treatment 
for these studies were pre-optimized for maximal effects on cytoplasmic process elongation (data not 
shown). Following cell treatment, the protein level of the Kalirin isoforms was determined by Western 
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blotting. In addition, the phosphorylation of extracellular regulated kinase (ERK), which was previously 
implicated in osteoblast signaling downstream of Kalirin (Huang et al. unpublished data), was examined. 
As shown in Figure 15, the cytoplasmic processes of MLO-Y4 cells were significantly lengthened after 5-
7 days of treatment, with 75 ng/ml NGF and 50 mM KCl inducing maximal morphological responses.  
Western blot analysis using isoform-specific antibodies to Kalirin revealed a dose-dependent increase in 
Kalirin-7 and Kalirin-12 in cells treated with NGF (Figure 16). Consistent with the increase in Kalirin, the 
level of total RhoA was increased, whereas Rac1 protein levels remained the same. In contrast, Kalirin-7, 
Kalirin-12 and RhoA protein levels were reduced in MLO-Y4 cells treated with KCl, compared to vehicle 
treated controls. 
 
6. The Kalirin-12 kinase domain regulates cytoplasmic process formation in MLO-Y4 cells 
To examine the mechanism of action of Kalirin in regulating cytoplasmic process formation, MLO-Y4 
cells were electroporated to express Kalirin functional domain. Mammalian expression constructs 
encoding GEF1, GEF2, Ig/FnIII or the Kalirin-12 Ser-Thr kinase domain were used (see Figure 6).  Two 
plasmid expression constructs for the Kalirin-12 Ser-Thr kinase domain were used; in Kal-kinase1, the 
GFP-tag was directly linked to the C-terminal end of the kinase domain, whereas in Kal-kinase2 the GFP 
expression was under the control of a separate promoter and was co-expressed with the kinase-domain 
(see Figure 6). Although all expression constructs generated protein products of the correct molecular 
weight in control non-osteocytic cells (data not shown), only the Ser-Thr kinase domain of Kalirin-12 was 
successfully expressed in the MLO-Y4 osteocytic cell line (Figure 17). The electroporation efficiency of 
Kal-kinase1 and Kal-kinase2 cDNA constructs was approximately 80% and 60% respectively (Figure 
18). Following electroporation of Kal-kinase1 or Kal-kinase2 the morphology of MLO-Y4 cells was 
examined by microscopy. Changes in the actin cytoskeleton were observed by labeling with rhodamine 
phalloidin (red), while Kal-kinase expression was detected by virtue of the GFP tag. The pEGFP empty 
vector, which also expresses GFP, and non-electroporated cells were used as negative controls. As shown 
in Figure 18, MLO-Y4 cells expressing the Kal-kinase domain (green) exhibited changes in the 
appearance of their cytoplasmic processes (red), compared to empty vector or non-electroporated control 
cells. Specifically, short cytoplasmic processes with extensive branching were observed in MLO-Y4 cells 
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expressing the Kal-kinase domain (Figure 18; arrows), compared with the pEGFP empty plasmid or non-
electroporated cells. 
 
MLO-Y4 cells expressing the Kal-kinase1 and Kal-kinase2 cDNA expression constructs were also 
examined by Western blotting. The expression of Kal-kinase1 and Kal-kinase2 was determined using an 
antibody to the myc tag. We also examined if over-expression of the kinase domain affected Rac1 and 
RhoA protein levels, as well as the phosphorylation of ERK (pERK), which was reported to play a role in 
Kalirin signaling mechanisms
89
. Electroporation appeared to induce the phosphorylation of ERK 
compared to cells electroporated with pEGFP.  Nevertheless, examination of MLO-Y4 cells expressing 
Kal-kinase1 and Kal-kinase2 showed a higher ratio of pERK to total ERK, compared to control 
electroporated cells. Similar to MLO-Y4 cells treated with increasing concentrations of NGF, no change 
in Rac1 levels was observed in cells expressing Kal-kinase1 or Kal-kinase2. Moreover, MLO-Y4 cells 
expressing the kinase domain of Kalirin-12 had higher levels of RhoA than control cells. 
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Proteins Functions 
Alkaline phosphatase (ALP) Marker of bone metabolism
90
 
β-catenin Involved in the differentiation of mesenchymal progenitor cells via the Wnt 
pathway
91
 
Collagen type I Marker for bone formation
92
 
Core-binding factor alpha 1 
(Cbfa1) or 
Runt-related transcription 
factor 2 (Runx2) 
Required for the differentiation of mesenchymal stem cells into the osteoblast 
lineage and for embryonic bone formation
93
 
Is upregulated by BMP2 and Wnt pathways during osteoblast differentiation
93
 
Keratocan Regulation of cell proliferation and differentiation of osteoprogenitor linage cells
94
 
Osteocalcin (OCN) Marker of osteogenic maturation and bone turnover
95
 
Ca
2+
 binding protein
95
 
Osteopontin (OPN) Mediates binding between the bone matrix and the vitronectin receptors expressed 
in the sealing zone of osteoclasts
96
 
Osteoprotegerin (OPG) Negative regulation osteoclastogenesis
97
 
Osterix Involved in immature osteoblasts differentiation into pre-osteoblasts
98
 
Receptor activator of 
nuclear factor kappa-B 
ligand (RANKL) 
Cytokine secreted by osteoblasts that regulates osteoclast activation and 
differentiation
16
 
Bone sialoprotein Bone mineralization and bone growth
99
 
Marker of the late stages of osteoblast differentiation and the early stages of 
mineralization
99
 
 
 
TABLE 1. Osteoblast signaling and regulatory proteins. 
The table shows different proteins which are specifically expressed in osteoblasts, and their functions.  
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Proteins Functions 
Dentin matrix protein 1 
(DMP1) 
Cytoplasmic process formation
100
 
Binding to CD44, which interacts with adapter proteins that link to actin cytoskeleton
101
 
Regulates mineralization and mineral metabolism
102
 
Regulates the maturation of osteocytes and phosphate metabolism
103
 
Expressed in the pericellular matrix, cytoplasmic processes, osteocyte lacuna-canaliculi 
system and several parts of bone; metaphyseal primary trabeculae (bone modeling 
region) and secondary trabeculae (bone remodelling region) as well as cortical 
bone
104,105
 
Marker for the transitioning of osteoblasts into osteocytes
106
 
DMP1 is detected after osteopontin, osteocalcin and bone sialoprotein are activated
106
 
Estrogen receptor α1  Involved in the responsiveness of osteocytes to mechanical stress and the apoptosis of 
osteocytes
107
 
Prevalently presented in the osteocytes in cortical bones
107
 
Estrogen receptor β1  Involved in the responsiveness of osteocytes to mechanical stress and the apoptosis of 
osteocytes
107
 
Predominantly presented in the osteocytes in cancellous bone
107
 
Fibroblast growth factor 
23 (FGF23) 
Regulates renal phosphate excretion
102
 
Regulates the level of phosphorus and Vitamin D metabolisms
108
 
Inhibits osteoblast maturation by disrupting the Wnt signaling pathway
109
 
FGF-23 is regulated by PHEX
108
 
Matrix extracellular 
phosphoglycoprotein 
(MEPE) 
Phosphate homeostasis
82
 
Inhibits bone formation
110
 
Regulates the mineralization process
111
 
Up-regulates osteoprotegerin (OPG)
112
 
Phosphate-regulating gene 
with homology to 
endopeptidases on the X 
chromosome (PHEX) 
Phosphate homeostasis
82
 
Regulates MEPE
113
 
Podoplanin (E11/gp38) A marker of embedded osteoid osteocytes
102
 
Regulated the dendritic and canaliculi formation
102
 
Receptor activator of 
nuclear factor kappa-B 
ligand (RANKL) 
Cytokine secreted by osteocytes that regulates osteoclast activation and differentiation
16
 
Sclerostin (SOST) Inhibits the proliferation and differentiation of osteoblasts
114
 
Stimulates the apoptosis of osteoblasts
115
 
Inhibits bone formation by antagonizing Wnt/β-catenin pathway116,117 
The impairment of this gene in mice leads to high bone mass
117
 
 
TABLE 2. Osteocyte signaling and regulatory proteins. 
Different proteins which are specifically expressed in osteocytes and their functions are summarized in the table.  
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Antibodies Company Concentration 
Mouse monoclonal anti-Myc antibody (Clone 9E10) 
Santa Cruz Biotechnology, 
Inc, Dallas, TX, USA 
1:1000 
Mouse monoclonal anti-green fluorescent protein (GFP) 
antibody (Clone JL-8); Living colors
®
 
Clontech Laboratories, 
Inc.,Mountainview, CA, 
USA 
1:1000 
Rabbit polyclonal anti-Kalirin sec14 antibody              
(Clone CT301)  
From RE. Mains and         
BA. Eipper, UConn, CT 
1:1000 
Rabbit polyclonal Anti-COOH terminus of kalirin-12 
antibody (Clone Ab3225) 
61
 
From RE. Mains and BA. 
Eipper 
1:1000 
Rabbit monoclonal anti-P-p44/42 MAPK antibody 
(PhosphoERK) 
Cell Signaling Technology, 
Inc., Danvers, MA, USA 
1:1000 
Rabbit polyclonal anti-ERK1 antibody                          
(Total ERK) 
BD Biosciences, San Jose, 
CA, USA 
1:1000 
Mouse monoclonal anti-Rac1 antibody (Clone 23A8) 
Millipore Corporation, 
Billerica, MA, USA 
1:1000 
Rabbit polyclonal anti-Kalirin antibody  
Millipore Corporation, 
Billerica, MA, USA 
1:200 
Rabbit polyclonal with horseradish peroxidase conjugated 
Promega Corporation, 
Madison, WI, USA 
1:10000 
Mouse monoclonal with horseradish peroxidase conjugated 
Promega, Corporation, 
Madison,WI, USA 
1:20000 
 
TABLE 3. Antibodies for Western blotting and immunofluorescent staining. 
The table shows different antibodies and their concentrations for Western blot assays and immunofluorescent 
staining of primary osteocytes and MLO-Y4 osteocytic cells used in this study. 
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Primers Primer sequences Expression 
Temperature (°C) 
Melting  Annealing 
18S 
Forward: AGTCCCTGCCCTTTGTACACA 
Reverse: CGATCCGAGGGCCTCACTA 
Housekeeping gene 60.5 56 
Dentin matrix protein 1  
(DMP1) 
Forward: TCAGGACAGTAGCCGATCCA 
Reverse: TCCCCGATGGGTTTGTTGTG 
Differentiating osteoblasts 
Early osteocytes 
106
 
Highly expressed in osteocytes 
46,82
 
60 56 
Fibroblast growth factor 23 
(FGF23) 
Forward: GTGTCAGATTTCAAACTCAG 
Reverse: GGATAGGCTCTAGCAGTG 
Highly expressed in osteocytes 
82,118,119
 
Low expressed in osteoblasts 
118,119
 
52 56 
Estrogen receptor-α 
Forward: CTCAACCGCCCGCAGCTCAA 
Reverse: GTAGGCGATGCCCGACTGGC 
Growth plate cartilage 
120
 
Strongly expressed in osteoblasts, 
osteocytes 
86
, and osteoclasts 
120
 in 
cortical bones 
65 60 
Estrogen receptor-β 
Forward: ACCCTCACTGGCACGTTGCG 
Reverse: GGCTTGCGGTAGCCAAGGGG 
Growth plate cartilage 
121
 
Strongly expressed in osteoblasts and 
osteocytes in cancellous bone 
86
 
65 63 
Matrix extracellular 
phosphoglycoprotein  
(MEPE) 
Forward: TCAAGACAGCATTCACAAGGAC 
Reverse: GGAGGGCAGCACCATACC 
Predominantly expressed in osteocytes 
No expression in osteoblasts 
46,82,111,112
 
58.8 56 
Osteoprotegerin  
(OPG) 
Forward: ACCCAGAAACTGGTCATCAGC 
Reverse: CTGCAATACACACACTCATCACT 
Osteoblasts 
97
 
Osteocytes 
112
 
59 56 
Phosphate-regulating gene 
with homology to 
endopeptidases on the X 
chromosome  
(PHEX) 
Forward: TGATGGAAGCAGAAACAG 
Reverse: CTTGGAAACTTAGGAGACC 
Osteocytes 
82,112
 52 56 
Podoplanin  
(E11/gp38) 
Forward: AGCCCAGTCCTAAGCATCCA 
Reverse: CGTGGCTCCTCAACTCATCG 
Early osteocytes 
Osteoblasts differentiate into osteocytes 
100
 
60 56 
Receptor activator of 
nuclear factor kappa-B 
ligand  
(RANKL) 
Forward: TCCTGTACTTTCGAGCGCAC 
Reverse: CCAGAGTCGAGTCCTGCAAA 
Osteoblasts 
97
 
Osteocytes 
112
 
59 56 
Sclerostin  
(SOST) 
Forward: CCACAAAGACTGAAAGCCGC 
Reverse: TAACAATGCCTCTGGTCGGG 
Restrictedly expressed in osteocytes 
115
 59.75 56 
Kalirin-7 
Forward: GATACCATATCCATTGCCTCCAGGACC 
Reward: CCAGGCTGCGCGCTAAACGTAAG 
Hippocampus and the cerebral cortex of 
the brain 
122
 
61 57 
Kalirin-9 
Forward: GCCCCTCGCCAAAGCCACAGC 
Reward: CCAGTGAGTCCCGTGGTGGGC 
Growth cones of the axon and neurites
67
  62 59.5 
Kalirin-12 
Forward: CTTCATAGAACGCCGCAAGC 
Reverse: ACCTCAGGGGTTGTGGGATA 
Neurons 
61,122
 61 57.5 
 
TABLE 4. Oligonucleotide primers used for QPCR. 
The table shows the oligonucleotide primer sequences and their melting and annealing temperatures, including 
information regarding the expression of each gene in different tissues. These primers are specific to the selected 
genes. 
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  Genotype Mean±SE p-value 
Number of processes 
WT 4.69±0.3 
0.0004  
KO 3.32±0.21 
Length of processes 
WT 85.4±3.6 
0.0276  
KO 79.5±4.6 
Number of osteocytes 
WT 93.4±4.7 
0.2243  
KO 83.6±2.6 
 
TABLE 5. Analysis of osteocyte cytoplasmic processes from Kal-KO and WT mice. 
The chart summarizes data comparing the number and length of cytoplasmic processes detected in cultured 
osteocytes from WT and Kal-KO mice. To determine the number and length of cytoplasmic processes, a total 
number of 68 WT and 78 Kal-KO osteocytes were examined from one preparation of cells isolated from mouse 
femur and tibia (pooled samples). Microscopic analysis revealed that Kal-KO osteocytes have significantly shorter 
and fewer cytoplasmic processes compared to WT osteocytes (p<0.05). The average numbers of osteocytes 
embedded in cortical bones from WT (6 independent bone sections) and Kal-KO (8 independent bone sections) 
mice, as determined by basic fuchsin-staining, are also shown. There is no statistic different in number of osteocytes 
between WT and Kal-KO groups (p>0.05). All data was analyzed using the Wilcoxon rank sum tests.  
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FIGURE 1. Schema for mesenchymal stem cell differentiation into osteoblasts.  
Osteoblasts are specialized fibroblasts which are able to secrete and mineralize the bone matrix. They differentiate 
from mesenchymal stem cells. Osteoblast differentiation involves the interaction of transcription factors as well as 
endocrine, paracrine and autocrine factors. BMP-2 induces Cbfa1 activity in mesenchymal stem cells 
123
. Cbfa1 
directs mesenchymal stem cells to commit to an osteoblast pathway 
124
. TGF-β regulates the proliferation of 
undifferentiated mesenchymal stem cells and the differentiation of osteoprogenitor cells 
125
. Growth factors (BMP, 
TGF, IGF, VEGF and FGF) also support the recruitment and proliferation of osteoprogenitor cells 
125
.  
 
Osteoprogenitor cells differentiate into pre-osteoblasts depending on several regulatory factors. Osterix is important 
to shifting bipotent osteoprogenitor cells from the chondrocytic lineage to the osteoblastic lineage 
126
. IGF and PGE2 
promote the proliferation and differentiation of osteoprogenitor cells to pre-osteoblasts 
127
. PTH balances the 
differentiation of osteoprogenitor cells by inhibiting the late stage of differentiation of osteoprogenitor cells to pre-
osteoblasts 
128
. Pre-osteoblasts differentiate into osteoblasts via an increase the activity of Cbfa1 and increases in the 
expression of collagen type I, BSP, OPN, ALP and Galectin-3, and begin to express OCN 
123
. The mature 
osteoblasts further differentiate into either bone lining cells or osteocytes.  
 
BMP: Bone morphogenic protein; TGF: Transforming growth factor; IGF: Insulin-like growth factor; VEGF: 
Vascular endothelium growth factor; FGF: Fibroblast growth factor; PTH: Parathyroid hormone; (OSF-)-1 
osteoblast stimulating factor or pleiotrophin (PTN) or heparin-binding growth-associated molecules (HB-GAM), 
Cbfa1: Core-binding factor alpha 1 or Runt-related transcription factor 2 (Runx2); PGE2: Prostaglandin E2; BSP: 
Bone sialoprotein; OPN: Osteopontin; ALP: Alkaline phosphatase and OCN: osteocalcin.   
 
Osteoprogenitor cell Pre-osteoblast 
Osteocyte 
Mesenchymal stem cell 
IGF, PTH, (OSF-)-1 
PGE2, Osterix 
BMP-2, TGF-β, IGF, 
VEGF, FGF-2, Cbfa1 
Bone lining cell 
Osteoblast 
Collagen type I, BSP, OPN and ALP 
Collagen type I, BSP, 
OPN, ALP and Galectin-3 
Collagen type I, BSP, OPN, 
ALP, Galectin-3 and OCN 
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FIGURE 2. Schema describing the osteocyte differentiation process.  
Mature osteoblasts express Cbfa1, Osterix, ALP and OCN. When they start to embed in the bone matrix, osteoblasts 
undergo a differentiation process toward osteoid osteocytes, mineralizing osteocytes and finally to mature 
osteocytes. E11/gp38 is one of the earliest specific proteins to be expressed during osteoblasts-to-osteocyte 
transition (osteoid osteocytes) 
100
. DMP1 has high calcium ion-binding capacity 
105
, so it is expressed only in 
mineralized tissue 
105,129
. DMP1 is a marker of transitioning osteocytes, and is expressed in young osteocytes. PHEX 
and MEPE regulate mineralization during osteocyte differentiation. MEPE is stimulated by Wnt3a and functions to 
inhibit bone mineralization by osteoblasts
130,131
. PHEX promotes bone mineralization. PHEX binds with high 
specificity to MEPE 
132
 to protect MEPE from proteolysis by cathepsin B
113
. Mature osteocytes express specific 
markers such as FGF23 which regulates phosphate homeostasis and sclerostin, which is an inhibitor of Wnt 
signaling and inhibits the proliferation and differentiation of osteoblasts 
85
. 
 
ALP: Alkaline phosphatase; OCN: Osteocalcin; MEPE: Matrix extracellular phosphoglycoprotein; PHEX: 
Phosphate-regulating gene with homology to endopeptidases on the X chromosome; DMP1: Dentin matrix protein 1 
and FGF23: Fibroblast growth factor 23.    
 
 
 
 
 
 
 
 
 
 
Osteoid 
Mineral 
Osteoblasts Osteoblastic 
osteocytes 
Osteoid osteocytes 
Mineralizing osteocytes 
      (young osteocytes) 
Mature osteocytes 
PHEX 
MEPE 
E11/gp38 
DMP1 
PHEX 
MEPE 
Sclerostin 
FGF23 
Cbfa1 
Osterix 
ALP 
OCN 
37 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
FIGURE 3.  Signaling between bone cells.  
Bone cells signal to each other via a number of cytokines and ligand-receptor interactions. Osteocytes 
secrete RANKL and M-CSF to activate osteoclast proliferation and differentiation, and this process is 
balanced by competitive binding of OPG to RANKL. IGF-1 from osteocytes induces osteoblast 
proliferation and differentiation. Nitric oxide activates osteoblast functions while sclerostin inhibits 
osteoblast functions. Osteoblasts also secrete RANKL, M-CSF, OPG as well as OSCAR, to regulate 
osteoclast proliferation and differentiation. Mature osteoclasts secrete BMPs and Wnt10b to activate 
osteoblast functions
133
 and promote osteoblastogenesis
134
 respectively.  The ephrin (ligand)-EPH 
(receptor) complex is important for communication between osteoblasts and osteoclasts and regulates the 
activities of both cells, including regulating the differentiation of osteoblast lineage cells
135
.    
 
RANKL: Receptor activator of nuclear factor kappa-B ligand, M-CSF: macrophage colony-stimulating 
factor, OPG: Osteoprotegerin, OSCAR: osteoclast-associated receptor, BMP: bone morphogenetic 
protein, IGF: Insulin-like growth factor and Ephrin: Eph receptor interacting protein.   
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FIGURE 4. The domain structure of Kalirin isoforms.  
Common domains of all three Kalirin major isoforms are Sec14, spectrin-like repeats and GEF1. Kalirin-9 is larger 
than Kalirin-7 with an additional GEF-2 domain. Kalirin-12 is the largest isoform with an additional GEF2, Ig, FnIII 
and Ser/Thr kinase domains. 
 
DH: Dbl homology, PH: pleckstrin homology, GEF: guanine nucleotide exchange factor, SH3: Src homology 
domain, Ig: immunoglobulin-liked domain, FnIII: fibronectin III domain, and Ser/Thr: serine/threonine protein 
kinase domain. 
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FIGURE 5. Mice tibias and femurs before and after bone marrow removal. 
For osteocyte isolation, the bone marrow of tibias and femurs were flushed with sterilized PBS.  Mice tibias and 
femurs before (A) and after (B) flushing with sterilized PBS are shown.  
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Name Vector Insert Size of insert 
Total 
(kDa) 
Kal-kinase1 pEGFP.Hismyc.Kal-kinase   
(GFP tagged) 
 
EGFP 
Histidine 
Myc 
Kalirin Kinase 
238 amino acids (26.9 kDa) 
0.840 kDa 
1.202 kDa 
328 amino acid (36 kDa) 
65 
Kal-kinase2 pCMS.Hismyc.Kal-kinase 
(GFP co-expressed on a 
separate promoter) 
Histidine 
Myc 
Kalirin Kinase 
0.840 kDa 
1.202 kDa 
328 amino acid (36 kDa) 
38 
 pEGFP plasmid GFP 238 amino acids  26.9 
 
FIGURE 6. Domain structure of the Kalirin cDNA expression constructs. 
(A) Schematic representation of the Kal-kinase1 (I) and Kal-kinase2 (II) cDNA expression plasmids are shown. 
Kalirin was tagged with histidine (His) and myc. (B) The predicted molecular weights of the protein domains are 
shown. The molecular weight of inserts is used to interpret Western blot assay results. 
I. II. 
A. 
B. 
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FIGURE 7.  Determination of Kalirin mRNA and protein levels in osteocytes.  
(A) The expression of Kalirin isoform mRNA levels in primary osteocytes (n=4) was quantified by QPCR. All three 
major isoforms are expressed.  (B) The expression of Kalirin isoforms in MLO-Y4 cells was detected by Western 
blot analysis. Kalirin-7 was more highly expressed than Kalirin-9 at the protein level. 
 
 
 
 
 
 
 
A. 
B. 
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FIGURE 8. Immunofluorescent labeling of Kalirin in primary osteoblasts. 
The immunofluorescent labeling of Kalirin (green), actin filaments (red), nuclei (blue) and composite of primary 
osteoblasts. The expression of Kalirin is at the perinuclear region and extending from the nucleus to the cell 
periphery.  
Osteoblasts 1 Osteoblasts 2 
Kalirin 
Actin 
Nuclei 
Composite 
43 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
FIGURE 9. Immunofluorescent labeling of Kalirin in WT osteocytes. 
The immunofluorescent labeling of Kalirin (green), actin filaments (red), nuclei (blue) and composite of WT 
osteocytes. Kalirin is localized to the perinuclear region and along the cytoplasmic processes, extending out to the 
tips of the processes of primary osteocytes.  
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FIGURE 10. Immunofluorescent labeling of Kalirin in MLO-Y4 cells. 
The immunofluorescent labeling of Kalirin (green), actin filaments (red), nuclei (blue) and composite of MLO-Y4 
cells. Similar to primary osteocytes, Kalirin is localized to the perinuclear region in MLO-Y4 cells.  
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FIGURE 11. Basic fuchsin staining of osteocytes in cortical bone.  
(A) Basic fuchsin stained osteocytes in lacuna in the cortical bones from the distal femurs of WT and Kal-KO mice.  
(B) Comparison of the number of osteocytes in tibias and femurs from WT and Kal-KO mice is shown. Statistical 
analysis was performed using mixed-model ANOVA (n=10).  The number of osteocytes in cortical bone of WT and 
Kal-KO mice was not found to be statistically different (p>0.05). 
p = 0.2243 
WT Kal-KO 
A. 
B. 
50 μm 50 µm 
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FIGURE 12. Analysis of osteocytes from Kal-KO and WT mice by SEM.  
Representative SEM images after acid-etching of female long bones from Kal-KO and WT mice reveal osteocytes in 
lacuna. WT and Kal-KO osteocytes have numerous cytoplasmic processes extending from their cell bodies and 
joining the processes of adjacent cells (arrows).   
 
WT Kal-KO 
47 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
FIGURE 13. The morphology of primary osteocytes from WT and Kal-KO mice.  
(A) A morphology of osteocytes from the tibias and femurs of WT and Kal-KO mice (n=8 and 7, respectively) 
cultured on collagen-coated plates for one month after isolation.  (B) The average length and number of cytoplasmic 
processes per cell in WT and Kal-KO osteocyte (n=68 and 78 cells, respectively) is shown.  Kal-KO osteocytes have 
significantly shorter and fewer processes than the WT group (p<0.05 base on the Wilcoxon rank sum test). 
II. 
* 
p = 0.0004 
I. 
A. 
B. 
WT Kal-KO 
* 
p = 0.0276 
p = 0.0004 
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Detector Mean±SE p-value 
E11/gp38 1.07±0.42 0.84 
OPG 0.50±0.09 0.0313 
RANKL 4.25±2.01 0.11 
SOST 0.45±0.1 0.0156 
DMP1 0.70±0.21 0.31 
FGF23 0.73±0.32 0.63 
MEPE 0.43±0.1 0.0313 
Phex 0.46±0.17 0.08 
ER alpha 0.51±0.1 0.0156 
ER beta 13.26±7.94 0.0313 
IGF-1 0.49±0.13 0.0313 
 
FIGURE 14. Comparison of mRNA expression levels in WT and Kal-KO osteocytes. 
The expression of specific osteocyte genes detected in WT and Kal-KO osteocytes was quantified by QPCR, 
normalized to 18S RNA and compared.  The experiment was repeated 4 times and results from all experiments were 
averaged. Asterisks in the graph and highlighted p-values in a table show the statistic difference between WT and 
Kal-KO osteocyte genes.    
* * * * * 
* 
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FIGURE 15. The morphology of MLO-Y4 cells after treatment with NGF or KCl.  
Representative images of the morphology of untreated MLO-Y4 cells compared with cells treated with increasing 
concentrations of nerve growth factor (NGF-) or KCl for 5 days. (A, control; B, 25ng/ml NGF; C, 50 ng/ml NGF; 
D, 75 ng/ml NGF; E, 50 mM KCl). MLO-Y4 cells treated with high concentrations of NGF or KCl exhibit a distinct 
elongation of their cytoplasmic processes compared to untreated control cells.  Experiments were reproduced 4 
times. 
  
B. 
C. D. 
E. 
A. 
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FIGURE 16. Western blot analysis of MLO-Y4 cells treated with NGF or KCl. 
Western blot analysis of Kalirin-7, Kalirin-12, RhoA and pERK from total cell lysate of MLO-Y4 treated with 
increasing concentration of NGF or KCl. The highest expression of Kalirin-7, Kalirin-12, RhoA and pERK were 
observed in the 75 ng/ml NGF treatment group in which cytoplasmic processes were elongated (see Figure 13). 
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FIGURE 17. Western blot analysis of MLO-Y4 cells expressing the Kalirin-12 kinase domain.  
The Kalirin-12 kinase domain was expressed in MLO-Y4 cells by electroporation. The expression constructs for the 
Kalirin-12 kinase domain each contained a myc tag which was detected with an anti-myc antibody by Western blot 
assay. The myc blot represents the expression level of the kinase domain after electroporation. Controls included 
non-electroporated cells and cells electorporated with a PE plasmid (empty plasmid). The expression of pERK and 
RhoA in Kal-kinase domain expressing cells were higher than the negative control groups. 
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FIGURE 18. Immunofluorescent labeling of MLO-Y4 cells expressing the Kalirin-12 kinase domain. 
Kalirin Ser-Thr kinase domain plasmids (pEGFP.Hismyc.Kalkinase and pCMS.Hismyc.Kalkinase) tagged with GFP 
were transfected into MLO-Y4 cells by electroporation. The control group was transfected with empty pGFP 
plasmid, expressing GFP. Transfected MLO-Y4 cells were detected by virtue of GFP (green) while the actin 
cytoskeleton was detected by staining with rhodamine phalloidin (red). Cells expressing the Ser-Thr kinase domain 
(green cells) exhibit more branching of their cytoplasmic processes compared with non-transfected cells (not 
expressing GFP).    
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FIGURE 19.  Working model for the mechanism of action of Kalirin in osteocytes.  
In wild-type osteocytes, external stimuli such as nerve growth factor activates Kalirin. Activated Kalirin 
promotes RhoA-GTP binding, resulting in the reorganization of actin cytoskeleton and the elongation of 
the cytoplasmic processes in osteocytes. In addition, the Ser-Thr kinase of Kalirin potentially leads to the 
phosphorylation of ERK, which in turn may lead to OPG and SOST transcription. In the absence of 
Kalirin, changes in the length of osteocyte dendritic spines as well as decreased secretion of OPG and 
sclerostin may potentially regulate osteocyte communication, osteoclast differentiation and osteoblast 
activity, respectively.   
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Osteocytes are deeply embedded within the mineralized bone matrix, making their biology difficult to 
examine. As a result, much less is known about this cell type than osteoblasts, from which they are 
differentiated. In 2010, Kramer et al. reported that genetically modified mice lacking -catenin only in 
osteocytes (driven by the DMP1-Cre promoter), exhibited progressive bone loss, growth retardation and 
premature lethality. Cancellous bone mass was almost completely absent and cortical bone thickness was 
severely reduced 
136
. In other studies, it was shown that the cytoplasmic processes of osteocytes are very 
important for osteocyte viability and their ability to communicate with each other as well as osteoblasts 
and osteoclasts 
137
. In addition, osteocytic processes regulate the cell’s ability to respond to mechanical 
stimuli, fluid shear stress and changes in circulating levels of hormones, calcium or phosphate. However, 
a clear mechanistic understanding of the extension/retraction of the osteocyte cytoplasmic processes and 
their role in bone homeostasis is lacking.   
 
Most studies to date have focused on the role of the novel GEF protein, Kalirin, in brain tissue and 
neuronal plasticity. Kalirin-7 mRNA was the most abundant isoform found in neurons of the central 
nervous system 
58
. Kalirin-9 and Kalirin-12 were found to be highly expressed during embryonic 
development, with Kalirin-7 protein levels increasing in adult brain 
58
. In the current study, the influence 
of Kalirin on the function of osteocytes and the formation of cytoplasmic processes in osteocytes was 
examined. QPCR analysis of Kalirin isoforms in primary osteocytes and MLO-Y4 osteocytic cells 
revealed that Kalirin-9 mRNA was more abundant than Kalirin-12, followed by Kalirin-7 mRNA. On the 
other hand, Western blot analysis indicated that Kalirin-7 was more highly expressed than Kalirin-9 and 
Kalirin-12. However, the latter finding may be due to differences in the specificity of the polyclonal 
antibodies used in these studies. Alternatively, it is possible that the isoforms exhibit differences in 
mRNA or protein stability. Further study is needed to clarify the expression and functions of the three 
major Kalirin isoforms in osteocytes.          
 
To examine the effects of Kalirin on the number of osteocytes, basic fuchsin staining of mouse distal 
femurs was used, which revealed a similar numbers of osteocytes in Kal-KO and WT cortical bones. To 
quantify differences in osteocyte cytoplasmic extensions, primary osteocytes were isolated and examined 
56 
 
in vitro using phase-contrast and immunofluorescent microscopy. The morphology of osteoblasts and 
osteocytes was found to be distinctly different, especially with the appearance of cytoplasmic processes in 
osteocytes. Primary osteocytes from WT mice contained an average of 4.7±0.3 cytoplasmic extensions 
per cell, which were 85±3.6 µm in length. In contrast, the number (3.3±0.2) and length (79.5±4.6 m) of 
cytoplasmic extensions in primary osteocytes from Kal-KO mice were significantly reduced. In 2005, 
Holmbeck et al. used Bodian silver stain to directly observe the length and number of processes of 
osteocytes in bone pieces from tibia and femur of WT mice. Cytoplasmic processes were found to be 4-8 
µm in length, and 9-26 cytoplasmic processes per osteocyte were reported 
29
. In 2006, Beno et al. 
reported 40-100 cytoplasmic processes per osteocyte 
138
. Thus, the number of osteocyte cytoplasmic 
processes reported in bone sections appears to be significantly higher than the number of processes 
identified in our studies using primary osteocytes cultured in vitro. The discrepancy in these findings may 
be due to the fact that the length of cytoplasmic processes in bone may be constrained by the mineralized 
matrix and the established canaliculi network, and by the number of neighboring osteocytes or other bone 
cells. In vitro, however, these physical constraints may be eliminated or reduced allowing for lengthening 
of cytoplasmic processes. The number and length of cytoplasmic processes may also be affected by 
plating density. Indeed, collagenase digestion of bone yields a small number of osteocytes, which when 
cultured are physically isolated from other osteocytes. As osteocytes re-establish a communication 
network, the lengthening of individual cytoplasmic processes may be favored rather than altering the 
number of processes per cell. Immunofluorescent staining also revealed the perinuclear localization of 
Kalirin in primary osteocytes (Figure 9) and MLO-Y4 cells (Figure 10). Kalirin also colocalized with a 
subset of radially-directed actin filaments which extended outwards towards the plasma membrane. Taken 
together, our studies demonstrate that Kalirin plays a role in regulating both the length and number of 
cytoplasmic extensions in primary osteocytes. Future studies will examine the effect of cell density on the 
length and number of cytoplasmic processes in primary osteocytes from WT and Kal-KO mice. 
 
After serial collagenase digestion of bones to isolate primary osteocytes, deeply embedded osteocytes 
remaining in bones were examined for changes in mRNA expression.  Several genes specific for 
osteoblasts or osteocytes were examined from these bones.  mRNA for SOST, DMP1 and E11/gp38 were 
57 
 
all detected.  In contrast, the expression of KERA, which is the specific marker for osteoblasts not 
detected (data not shown). Therefore, mature osteocytes were the main cellular source or RNA present in 
these bones.  
 
To examine the role of Kalirin on osteocyte function, QPCR analysis of osteocyte genes was performed. 
Several osteocyte markers were examined including markers for early osteoid osteocytes (MEPE, PHEX 
and E11/gp38), mineralized osteocytes (Dmp1) and mature osteocytes (FGF23 and SOST) 
139
. E11/gp38 
is the earliest osteocyte-specific protein (osteoid osteocytes), which is expressed early during the 
transition of osteoblasts to osteocytes 
100
. Although no change in the level of E11/gp38 was detected in 
Kal-KO osteocytes, potentially indication a similar number of osteocytes were present in these bone 
preparations, a significant decrease in MEPE mRNA was observed in Kal-KO osteocytes, compared to 
WT cells, suggesting that Kalirin may play a role in the mineralizing activity of osteocytes. QPCR 
analysis also revealed a decrease in SOST mRNA levels, suggesting that sclerostin secretion by Kal-KO 
osteocytes may be decreased. Since sclerostin is involved in antagonizing Wnt signaling in osteoblasts, 
resulting in an increase in β-catenin degradation 140,141.  These findings suggest that osteocyte-osteoblast 
communication may be impaired in the absence of osteocytic Kalirin.  The decrease in sclerostin mRNA 
suggested that osteoblast activity may be enhanced.  Consistent with this finding, unpublished findings 
from this laboratory suggest that the differentiation of early osteoblasts is enhanced in Kal-KO 
osteoblasts.  However, Kal-KO osteoblasts also exhibit a decrease in the mineralizing activity of mature 
osteoblasts, which may contribute to the decrease in cortical bone mass observed in Kal-KO female mice 
(Huang et al. unpublished data).   
 
The estrogen receptors (ERs) are nuclear hormone receptors which can initiate or enhance gene 
transcription 
142
. Osteocytes in cortical bone strongly express ER-α while osteocytes in trabecular bone 
predominately express ER-β 120. Moreover, low levels of estrogen or defects in estrogen signaling leads to 
bone loss, in part by promoting osteoclast survival 
143
. QPCR analysis revealed a decrease in ER- and an 
increase in ER- in Kal-KO compared to WT osteocytes. The osteocyte preparations for this study 
consisted of pooled cells from cortical and trabecular bone. The decrease of ER- and increase in ER- 
58 
 
mRNA levels may therefore indicate that estrogen-signaling is disrupted in Kal-KO mice, potentially 
contributing to the reduced bone mass of female Kal-KO mice. Consistent with this speculation, 
osteoclast number was increased in femoral sections of Kal-KO mice (Huang et al., unpublished studies). 
Osteoclast differentiation is also controlled by the ratio of RANKL and OPG, which acts as a decoy 
receptor for RANKL. QPCR analysis revealed a decrease in OPG mRNA levels in Kal-KO osteocytes, 
which could lead to alterations in the RANKL/OPG ratio and further promote osteoclast differentiation.  
 
Osteocytes express a large amount of IGF-1, which acts as an osteogenic growth factor to promote bone 
formation by osteoblasts 
144
. IGF-1 mRNA is also upregulated in osteocytes in response to mechanical 
loading 
145
. In transgenic mice in which IGF-1 over-expression was targeted to osteoblasts using the 
osteocalcin promoter, an increase in bone mineral density and bone volume was observed 
146
.  In addition, 
an increase in osteocyte lacunae occupancy was observed, suggesting that IGF-I may extend osteocyte 
life span. In osteocytes from Kal-KO mice, a decrease in IGF-1 mRNA levels was observed by QPCR, 
suggesting that osteocyte life-span may be decreased in Kal-KO mice compared to WT osteocytes. Kal-
KO mice may also be less responsive to mechanical loading. However, the physiological consequence of 
reduced IGF-1 mRNA levels in Kal-KO osteocytes remains to be determined.   
 
Overall, QPCR analysis of osteocytes from WT and Kal-KO mice suggest defects in the function of 
osteocytes as well as their ability to regulate the activities of osteoblasts and osteoclasts.  However, at this 
time, we cannot exclude the possibility that sequential collagenase digestions from WT and Kal-KO 
bones (which are osteoporotic) did not lead to the isolation of a different subset of osteocytes from the 
different mice genotypes.  Future studies will include comparing the expression of osteocyte mRNA 
levels in collagenase and non-collagenase treated bones as well as from isolated osteocytes. 
                       
To study the mechanism of Kalirin’s effects on cytoplasmic elongation in osteocytes, the functional 
domains of Kalirin were introduced into MLO-Y4 cells by electroporation. The cytoplasmic processes of 
MLO-Y4 cells over-expressing the Ser-Thr kinase domain of Kalirin-12 were found to be longer and 
more branched than control cells. Furthermore, an increase in the expression of phosphorylated ERK was 
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observed in cells expressing the Ser-Thr kinase domain. Of interest, mechanical stimulation promotes the 
survival of osteocytes by activating ERK signaling 
147
. Moreover, Plotkin et al. reported that ERK 
signaling was not activated by mechanical loading in ER-α and ER-β knock-down osteocytes 148. Based 
on these findings, it is possible that Kalirin may be involved in promoting cytoplasmic spine elongation in 
osteocytes via an ER- and/or ERK-dependent pathway following mechanical stimulation.  
 
High extracellular KCl has been shown to promote the elongation of cytoplasmic processes in neurons, 
which is dependent on chloride channel activation 
88
. Chakrabarti et al. also reported that Kalirin bound to 
the NGF receptor TrkA in neurons and induced the extension of dendritic processes of neurons
87
.  
Therefore, we speculated that osteocyte dendritic processes might be regulated by NGF or KCL.  
Interestingly, the cytoplasmic processes of MLO-Y4 cells were found to be dose-dependently increased in 
the presence of NGF. KCl-treated MLO-Y4 cells also showed significant elongation of their cytoplasmic 
processes compared to control cells. Western blot analysis further revealed that NGF dose-dependently 
increased the protein levels of Kalirin-7, Kalirin-12 and RhoA in MLO-Y4 cells. Although KCl-treated 
cells exhibited elongated cytoplasmic processes, the expression of Kalirin-7, Kalirin-12 and RhoA were 
lower than in the NGF-treated cells, suggesting that KCl promoted the elongation of cytoplasmic 
processes via a different intracellular mechanism than NGF. Furthermore, the ability of NGF to promote 
cytoplasmic process elongation appeared to involve Kalirin and RhoA, which is a known Kalirin GEF 
target.   Future studies will focus on understanding the mechanism of action of NGF and KCL on 
dendritic spine elongation in osteocytes, and on identifying the NGF receptors expressed in osteocytes, 
which currently remain unknown. 
 
 
 
 
 
 
 
60 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
SUMMARY AND CONCLUSIONS 
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Osteocytes are deeply embedded within the mineralized matrix, and play an essential role in the 
regulation of bone mass via cellular communication with osteoclasts and osteoblasts. Kalirin was found to 
be expressed in osteoclasts and osteoblasts and global deletion of Kalirin leads to a loss of trabecular and 
cortical bone mass. We examined the role of Kalirin on the morphology and function of osteocytes.  
Quantitative PCR (QPCR) and Western blotting revealed the expression of the three major Kalirin 
isoforms (Kal-7, Kal-9, Kal-12) in osteocytes, while immunofluorescent staining revealed Kalirin was 
localized to the perinuclear region and the cytoplasmic processes of osteocytes.  In the absence of Kalirin, 
the number and length of cytoplasmic processes were significantly reduced in osteocytes, suggesting 
Kalirin regulates cytoskeletal remodeling. Moreover, the mRNA levels of osteoprotegerin and SOST, 
which are important for controlling osteoclast differentiation and Wnt signaling leading to bone formation 
by osteoblasts, respectively, were reduced in Kal-KO osteocytes. Finally, MLO-Y4 cells treated with 
NGF, which is known to activate Kalirin in neurons, or over-expressing the Ser-Thr kinase domain of 
Kal-12, promoted cytoplasmic process elongation and upregulated phosphorylated ERK and RhoA levels.   
 
Overall, these results suggest that Kalirin controls osteocyte morphology and function in part by 
regulating cytoskeletal remodeling and the activity of ERK and RhoA. Kalirin is also involved in 
intercellular signaling via sclerostin and OPG to regulate both osteoblast function and osteoclast 
differentiation, respectively. Furthermore, Kalirin may regulate the bone remodeling process in vivo 
through direct and indirect effects on the function of osteoclasts, osteoblasts and osteocytes. 
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KALIRIN: NOVEL ROLE IN OSTEOCYTE FUNCTION 
K. Wayakanon*, S. Huang, P. Eleniste, M. Allen and A. Bruzzaniti 
Indiana University School of Dentistry, Indianapolis, IN 
Communication between bone cells is important for the maintenance of bone mass.  Although osteocytes 
are deeply embedded within the mineralized matrix, they are essential for the regulation of osteoblast and 
osteoclast functions. However, the intracellular proteins that control the morphology and function of 
osteocytes, and their ability to communicate with other bone cells are still unknown. Kalirin is a novel 
multi-domain GTP exchange factor (GEF) protein that activates the RhoGTPases. Recently, we found 
that 14 week old female Kalirin knockout (Kal-KO) mice exhibit a 45% decrease in trabecular bone 
density and have significantly lower cortical area, perimeter, thickness and polar cross-sectional moment 
of inertia (-12.6%, -7.2%, -7.6% and -21.9%, respectively) than WT mice. Kalirin was found to be 
expressed in osteoclasts and osteoblasts but its expression and function in osteocytes is currently unclear. 
We examined the role of Kalirin on the morphology and function of osteocytes. Primary osteocytes were 
isolated by sequential collagenase digestions from long bones (femurs and tibias) of 10-week old WT and 
Kal-KO mice. Immunofluorescent staining revealed Kalirin was localized to the perinuclear region of 
primary osteocytes and MLO-Y4 cells, and was detected along the cytoplasmic processes of primary 
osteocytes. We also examined primary osteocytes isolated from the long bones of Kal-KO and WT mice 
for changes in the length and number of cytoplasmic processes. Kal-KO osteocytes were found to express 
significantly fewer cytoplasmic processes per cell (3.3±0.21) than WT osteocytes (4.7±0.3). In addition, 
the cytoplasmic processes of Kal-KO osteocytes were shorter (79.5±4.6 µm) than those observed for WT 
osteocytes (85.4±3.6 µm) (p <0.01). Quantitative PCR revealed the expression of mRNA for the three 
major Kalirin isoforms (Kal-7, Kal-9, Kal-12) in primary osteocytes and in MLO-Y4 cells.  Moreover, the 
mRNA levels of osteoprotegerin (OPG) and SOST, which are important for controlling osteoclast 
differentiation and Wnt signaling leading to bone formation, respectively, were reduced in Kal-KO 
osteocytes. Next, the role of Kalirin in osteocyte morphology and function was further examined. 
Treatment of MLO-Y4 cells for 5 days with nerve growth factor, which is known to activate Kalirin in 
neurons, or over-expression of the Ser-Thr kinase domain of Kal-12, promoted cytoplasmic process 
elongation and upregulated phosphorylated ERK and RhoA levels. Together, these results suggest that 
Kalirin controls osteocyte morphology and function in part by regulating cytoskeletal remodeling and the 
activity of ERK and RhoA. Furthermore, Kalirin may control the bone remodeling cycle by regulating 
osteocyte signaling to osteoclasts and osteoblasts. 
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